The medical oncologist discusses the different talks that were presented at the International Kidney Cancer Symposium in Miami.
The next gen innovator discusses the integration of fields at the International Kidney Cancer Symposium in Miami.
Massachusetts General Hospital’s Severe Immunotherapy Complications Service focuses on the increasing number of “rare” cases of immunotherapy-related adverse events.
Treatment with lenvatinib and pembrolizumab has shown promise in patients with metastatic clear cell renal cell carcinoma who have already received an immune checkpoint inhibitor.
Autologous stem cell transplant has become safer over the years for patients with multiple myeloma and renal insufficiency.
The phase II IMmotion150 study evaluated disease- and treatment-related symptoms in RCC patients receiving atezolizumab alone or in combination with bevacizumab vs sunitinib.